MY140756A - Fused azole-pyrimidine derivatives - Google Patents

Fused azole-pyrimidine derivatives

Info

Publication number
MY140756A
MY140756A MYPI20033701A MYPI20033701A MY140756A MY 140756 A MY140756 A MY 140756A MY PI20033701 A MYPI20033701 A MY PI20033701A MY PI20033701 A MYPI20033701 A MY PI20033701A MY 140756 A MY140756 A MY 140756A
Authority
MY
Malaysia
Prior art keywords
pi3k
diseases
disease
present
disorders
Prior art date
Application number
MYPI20033701A
Inventor
Mitsuyuki Shimada
Kevin Bacon
Toshiki Murata
Kinji Fuchikami
Hideki Tsujishita
Naoki Omori
Issei Kato
Mami Miura
Klaus Dr Urbahns
Florian Dr Gantner
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MY140756A publication Critical patent/MY140756A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

THE PRESENT INVENTION RELATES TO NOVEL FUSED AZOLEPYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. THE FUSED AZOLEPYRIMIDINE DERIVATIVES OF THE PRESENT INVENTION EXHIBIT ENHANCED POTENCY FOR PHOSPHOTIDYLINOSITOL-3-KINASE (PI3K) INHIBITION, ESPECIALLY FOR PI3K- INHIBITION AND CAN BE USED FOR THE PROPHYLAXIS AND TREATMENT OF DISEASES ASSOCIATED WITH PI3K AND PARTICULARLY WITH PI3K- ACTIVITY. MORE SPECIFICALLY, THE AZOLE DERIVATIVES OF THE PRESENT INVENTION ARE USEFUL FOR TREATMENT AND PROPHYLAXIS OF DISEASES AS FOLLOWS: INFLAMMATORY AND IMMUNO-REGULATORY DISORDERS, SUCH AS ASTHMA, ATOPIC DERMATITIS, RHINITIS, ALLERGIC DISEASES, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), SEPTIC SHOCK, JOINT DISEASES, AUTO-IMMUNE PATHOLOGIES SUCH AS RHEUMATOID ARTHRITIS, AND GRAVES’ DISEASE, CANCER, MYO-CARDIAL CONTRACTILITY DISORDERS, HEART FAILURE, THROMBOEMBOLISM, ISCHEMIA, AND ATHEROSCLEROSIS. THE COMPOUNDS OF THE PRESENT INVENTION ARE ALSO USEFUL FOR PULMONARY HYPERTENSION, RENAL FAILURE, CARDIAC HYPERTOPHY, AS WELL AS NEURODEGENERATIVE DISORDERS SUCH AS PARKINSON’S DISEASE, ALZHEIMER’S DISEASE, DIABETES AND FOCAL ISCHEMIA, SINCE THE DISEASES ALSO RELATE TO PI3K ACTIVITY IN A HUMAN OR ANIMAL SUBJECT.
MYPI20033701A 2002-09-30 2003-09-29 Fused azole-pyrimidine derivatives MY140756A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30

Publications (1)

Publication Number Publication Date
MY140756A true MY140756A (en) 2010-01-15

Family

ID=32039115

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20033701A MY140756A (en) 2002-09-30 2003-09-29 Fused azole-pyrimidine derivatives

Country Status (32)

Country Link
US (2) US7511041B2 (en)
EP (2) EP1549652B1 (en)
JP (1) JP4790266B2 (en)
KR (1) KR101059652B1 (en)
CN (1) CN100384846C (en)
AR (2) AR041426A1 (en)
AT (2) ATE411996T1 (en)
AU (1) AU2003293310B2 (en)
BR (1) BRPI0314830B8 (en)
CA (1) CA2499134C (en)
CY (2) CY1109790T1 (en)
DE (1) DE60324296D1 (en)
DK (2) DK2042504T3 (en)
EC (2) ECSP055768A (en)
ES (2) ES2367141T3 (en)
HR (2) HRP20131159B1 (en)
IL (1) IL166855A (en)
MA (1) MA27483A1 (en)
MX (1) MXPA05001808A (en)
MY (1) MY140756A (en)
NO (1) NO331457B1 (en)
NZ (1) NZ539062A (en)
PE (1) PE20050089A1 (en)
PL (1) PL226562B1 (en)
PT (2) PT2042504E (en)
RU (1) RU2326881C9 (en)
SI (2) SI2042504T1 (en)
TW (1) TWI327570B (en)
UA (1) UA82205C2 (en)
UY (1) UY28001A1 (en)
WO (1) WO2004029055A1 (en)
ZA (1) ZA200503306B (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ZA200706595B (en) 2003-08-29 2008-06-25 Mitsui Chemicals Inc Insecticide for agricultural or horticultural use and method of use thereof
LT2612862T (en) 2004-05-13 2017-01-25 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US7691888B2 (en) 2004-10-07 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
JP2008537120A (en) 2005-04-14 2008-09-11 ザ トラスティーズ オブ ボストン ユニバーシティ Diagnosis of lung injury using classification prediction
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
JP2009529329A (en) 2006-03-09 2009-08-20 トラスティーズ オブ ボストン ユニバーシティ Methods for diagnosis and prognosis for lung diseases using gene expression profiles of nasal epithelial cells
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
PL2041139T3 (en) * 2006-04-26 2012-05-31 Hoffmann La Roche Pharmaceutical compounds
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (en) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED QUINAZOLINE USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISEASES ASSOCIATED WITH ANGIOGENESIS
EP1953163A1 (en) 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
JP2010539239A (en) * 2007-09-17 2010-12-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pyridopyrimidine derivatives as PI3 kinase inhibitors
CN101990577A (en) * 2007-09-19 2011-03-23 波士顿大学理事会 Identification of novel pathways for drug development for lung disease
CA2713388C (en) * 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
US20110105457A1 (en) * 2008-04-18 2011-05-05 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on pi3k
EP2303890A4 (en) * 2008-06-19 2012-04-11 Progenics Pharm Inc Phosphatidylinositol 3 kinase inhibitors
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
US8791131B2 (en) * 2008-09-30 2014-07-29 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
PL2364983T3 (en) * 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20170060179A (en) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 Therapies for hematologic malignancies
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
JP2012516329A (en) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Heteroaryls and their use as PI3K inhibitors
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP2012524126A (en) 2009-04-20 2012-10-11 ギリアド カリストガ リミテッド ライアビリティ カンパニー Method for treating solid tumors
RS53830B1 (en) * 2009-04-30 2015-06-30 Glaxo Group Limited INDASOLS SUBSTITUTED BY OXAZOLE AS PI3-KINASE INHIBITORS
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
KR20120063515A (en) * 2009-09-09 2012-06-15 아빌라 테라퓨틱스, 인크. Pi3 kinase inhibitors and uses thereof
EA201201414A8 (en) * 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх COMBINATIONS CONTAINING SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-c] HINAZOLINES
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2013538840A (en) 2010-10-01 2013-10-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Combinations containing substituted N- (2-arylamino) arylsulfonamides
UA113280C2 (en) * 2010-11-11 2017-01-10 AMINOSPIRT-SUBSTITUTED Derivatives of 2,3-Dihydroimimidase $ 1,2-c] QINAZOLINE, SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS, DISEASES AND DISEASES
CN103339133B (en) * 2010-11-11 2016-06-15 拜耳知识产权有限责任公司 2 of alkoxyl replacement, 3-glyoxalidine is [1,2-c] quinazoline also
US9675616B2 (en) 2010-11-11 2017-06-13 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines
JO3733B1 (en) 2011-04-05 2021-01-31 Bayer Ip Gmbh Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
ES2848273T3 (en) 2012-03-05 2021-08-06 Gilead Calistoga Llc Polymorphic forms of (S) -2- (1- (9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazoline-4 (3H) -one
EP2968988A4 (en) 2013-03-14 2016-11-16 Allegro Diagnostics Corp Methods for evaluating copd status
HK1214533A1 (en) 2013-03-15 2016-07-29 基因泰克公司 Methods of treating cancer and preventing cancer drug resistance
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
TWI710558B (en) 2013-05-01 2020-11-21 瑞士商赫孚孟拉羅股份公司 Biheteroaryl compounds and uses thereof
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
EP3083630B1 (en) 2013-12-20 2019-08-21 Gilead Calistoga LLC Process methods for phosphatidylinositol 3-kinase inhibitors
JP2017500319A (en) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー Polymorphic form of the hydrochloride salt of (S) -2- (1- (9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (en) 2014-11-05 2022-06-10 威拉赛特公司 Diagnostic system and method using machine learning and high-dimensional transcription data
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EA201791974A1 (en) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт COMBINATIONS CONTAINING SUBSTITUTE 2,3-DIHYDROIMIDAZO [1,2-С] HINAZOLIN
CN105130998B (en) * 2015-09-25 2017-07-28 苏州立新制药有限公司 Ku Pannixi preparation method
CN105130997B (en) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 A kind of Ku Pannixi preparation method
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US20190292600A1 (en) 2016-05-12 2019-09-26 Trustees Of Boston University Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
WO2018009915A1 (en) 2016-07-08 2018-01-11 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
AU2017376766A1 (en) 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
CA3054249A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft Formulations of copanlisib
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
WO2019101871A1 (en) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
CN112789279B (en) * 2018-07-27 2023-09-29 上海翰森生物医药科技有限公司 Inhibitors containing tricyclic derivatives, preparation methods and applications thereof
CN109053554B (en) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 Method for synthesizing 3-acetylpyridine by using catalyst
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
BR112021011894A2 (en) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited PHARMACEUTICAL COMPOSITION
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CN114621236B (en) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 Preparation method of quinoline feed additive
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) * 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
CN1033644C (en) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazoline derivatives, their preparation and use
FI970588A7 (en) 1994-08-12 1997-04-11 Wellstat Therapeutics Corp Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides
JP4431638B2 (en) * 1996-01-29 2010-03-17 アメリカ合衆国 Dihydropyridine-, pyridine-, benzopyran-one- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
DE60144277D1 (en) 2000-04-25 2011-05-05 Icos Corp HEMMER OF HUMAN PHOSPHATIDYL-INOSITOL-3-KINASE DELTA
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives

Also Published As

Publication number Publication date
EP2042504B1 (en) 2011-06-01
EP2042504A1 (en) 2009-04-01
US8129386B2 (en) 2012-03-06
EP1549652B1 (en) 2008-10-22
TW200413379A (en) 2004-08-01
WO2004029055A1 (en) 2004-04-08
ZA200503306B (en) 2006-07-26
NO20052076L (en) 2005-04-27
TWI327570B (en) 2010-07-21
US20060128732A1 (en) 2006-06-15
BR0314830A (en) 2005-08-16
SI2042504T1 (en) 2011-10-28
NO331457B1 (en) 2012-01-09
AR041426A1 (en) 2005-05-18
AU2003293310A1 (en) 2004-04-19
ES2367141T3 (en) 2011-10-28
DK1549652T3 (en) 2009-02-23
HRP20131159B1 (en) 2019-11-01
PL375935A1 (en) 2005-12-12
UY28001A1 (en) 2004-04-30
CA2499134C (en) 2011-12-20
PT1549652E (en) 2008-12-15
CN1688582A (en) 2005-10-26
IL166855A (en) 2014-05-28
AU2003293310B2 (en) 2010-04-01
US7511041B2 (en) 2009-03-31
RU2326881C2 (en) 2008-06-20
ECSP11005768A (en) 2011-03-31
BRPI0314830B8 (en) 2021-05-25
HRP20050375B1 (en) 2014-03-14
ES2312843T3 (en) 2009-03-01
ATE511510T1 (en) 2011-06-15
ECSP055768A (en) 2005-08-11
RU2005113165A (en) 2005-10-10
HK1084393A1 (en) 2006-07-28
NZ539062A (en) 2007-05-31
AR072458A2 (en) 2010-09-01
PE20050089A1 (en) 2005-04-20
JP4790266B2 (en) 2011-10-12
UA82205C2 (en) 2008-03-25
MXPA05001808A (en) 2005-08-16
CY1109790T1 (en) 2014-09-10
MA27483A1 (en) 2005-08-01
KR101059652B1 (en) 2011-08-25
HRP20050375A2 (en) 2006-05-31
PT2042504E (en) 2011-09-07
US20090270388A1 (en) 2009-10-29
DE60324296D1 (en) 2008-12-04
CN100384846C (en) 2008-04-30
SI1549652T1 (en) 2009-04-30
CY1112174T1 (en) 2015-12-09
JP2006508063A (en) 2006-03-09
ATE411996T1 (en) 2008-11-15
CA2499134A1 (en) 2004-04-08
EP1549652A1 (en) 2005-07-06
RU2326881C9 (en) 2009-04-10
BRPI0314830B1 (en) 2018-03-27
PL226562B1 (en) 2017-08-31
HRP20131159A2 (en) 2014-05-23
DK2042504T3 (en) 2011-09-19
KR20050067404A (en) 2005-07-01

Similar Documents

Publication Publication Date Title
NO20052076L (en) Fused azole-pyrimidine derivatives.
MXPA04004019A (en) Pyrimido [4,5-b] indole derivatives.
NO20070994L (en) N-hydroxide derivatives and their use
TW200714605A (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
WO2009050242A3 (en) Heterocycle-substituted piperazino-dihydrothienopyrimidines
SG155943A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
UA99309C2 (en) Substituted piperidino-dihydrothienopyrimidines
UA85597C2 (en) Quaternary salt ccr2 antagonists
MX2009008787A (en) 2-aminopyrimidine modulators of the histamine h4 receptor.
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NO20052796L (en) Indolylpyrazinone derivatives useful for the treatment of hyperproliferative disorders and disorders associated with angiogenesis
MY178156A (en) Compounds and their use as bace inhibitors
HRP20050318A2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes
NO20082508L (en) Aminopyrimidines useful as kinase inhibitors
NO20080125L (en) 2,6-quinolinyl derivatives, processes for their preparation and their use as a medicament
NO20075610L (en) New 5,7-disubstituted [1,3] thiazole [4,5-d] pyrimidin-2 (3H) -one derivatives
ATE516285T1 (en) DIHYDROPYRIDINONE DERIVATIVES
CA2793138C (en) Hydroxybenzoate salts of metanicotine compounds
NZ598096A (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
MXPA02001813A (en) Hydroxyalkanoyl aminolactams and related structures as inhibitors of a beta protein production.
WO2008039139A8 (en) Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
WO2010042649A3 (en) PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
MX2009003005A (en) Novel 5, 7-disubstituted [1, 3 ] thiazolo [4, 5-d] pyrimidin-2 (3h)-one derevatives and their use in therapy.
NO20070820L (en) Octahydropyrrolo (2,3, C) pyridine derivatives and their pharmaceutical use.
UA86399C2 (en) Normal;heading 1;heading 2;USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID IN THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF ANGIODEPENDENT DISEASES